Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EBIT (2021 - 2026)

HeartSciences (HSCS) has disclosed EBIT for 5 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 4.45% year-over-year to -$2.1 million, compared with a TTM value of -$8.2 million through Oct 2025, down 10.36%, and an annual FY2025 reading of -$8.4 million, down 32.46% over the prior year.
  • EBIT was -$2.1 million for Q4 2025 at HeartSciences, down from -$1.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$674446.0 in Q3 2021 and bottomed at -$2.4 million in Q1 2025.
  • Average EBIT over 5 years is -$1.6 million, with a median of -$1.7 million recorded in 2022.
  • The sharpest move saw EBIT tumbled 112.04% in 2022, then grew 19.17% in 2023.
  • Year by year, EBIT stood at -$956856.0 in 2021, then plummeted by 85.49% to -$1.8 million in 2022, then grew by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then dropped by 4.45% to -$2.1 million in 2025.
  • Business Quant data shows EBIT for HSCS at -$2.1 million in Q4 2025, -$1.9 million in Q3 2025, and -$1.9 million in Q2 2025.